J.P. Morgan initiates coverage on Insilico Medicine and XtalPi with Overweight ratings, optimistic on a multi-year rerating opportunity for China AIDD

Overview

This is a J.P. Morgan initiation report on China’s AI-driven drug discovery (AIDD) industry and two Hong Kong-listed companies, Insilico Medicine and XtalPi. The report believes the China AIDD industry is shifting from an algorithmic vision to industrial execution, with the investment opportunity driven by the combination of service and BD commercialization, clinical catalysts, revenue growth, and validation from collaborations with major pharmaceutical companies.

Core views

The report has three core views. First, AIDD significantly compresses early-stage drug discovery timelines, reduces capital consumption, and improves R&D success rates through generative AI, automated wet labs, and data-feedback closed loops. Second, China’s dense drug R&D supply chain, lower costs, faster R&D pace, and regulatory support give domestic AIDD companies structural execution advantages. Third, major pharmaceutical collaborations, clinical milestones, and non-dilutive revenue are validating AIDD’s transition from a technology theme into a commercializable business. The report recommends owning both Insilico and XtalPi: the former provides clinical catalysts and pipeline elasticity, while the latter offers the stability of infrastructure and service-based revenue.

Analysis framework

The report builds its investment conclusion by combining an industry framework, company business model breakdowns, R&D efficiency comparisons, clinical asset catalysts, Big Pharma transaction validation, peer valuation comparisons, SOTP segment valuation, and DCF cross-checks. For XtalPi, the focus is on evaluating AIDD services, robotic wet labs, AI4S, incubation projects, and platform licensing; for Insilico, the focus is on evaluating the Pharma.AI platform, proprietary pipeline, out-licensing potential, and clinical probability of success.

Methodology notes

• Valuation methodsSOTP

  Sum-of-the-parts valuation

  The report uses SOTP to assign appropriate industry multiples to different business segments, and adds an AI premium on top of traditional industry EV/S multiples to reflect the efficiency gains and commercialization potential brought by AIDD.

• Valuation methodsAI-empowered EV/S

  AI-empowered revenue multiple

  XtalPi’s chemical synthesis services are based on China CRO EV/S multiples plus an approximately 4x AI premium; Insilico’s drug discovery collaboration business is based on China biotech EV/S multiples plus an approximately 2x AI premium.

• Valuation methodsDCF cross-check

  Discounted cash flow cross-check

  The report uses DCF as a cross-checking tool for target prices, especially to test the reasonableness of SOTP valuation assumptions after long-term growth, margins, and risk adjustments.

• R&D frameworkDry-wet lab closed loop

  Dry-wet lab closed loop

  The dry lab uses generative AI to design molecules and predict properties, while the automated wet lab synthesizes and tests compounds, then feeds the experimental data back to the model, thereby forming an iterative data flywheel and an R&D efficiency moat.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Insilico Medicine (3696.HK)

  China AIDD high-elasticity pipeline and out-licensing exposure

  Strengths

  End-to-end Pharma.AI platform, deep proprietary pipeline, clinical assets such as Rentosertib, BD and out-licensing potential, and relatively high software-like gross margin.

  Weaknesses

  Revenue may fluctuate with transaction timing, and valuation is highly dependent on clinical probability of success and key asset milestones.

  Comparison

  Compared with XtalPi, Insilico is more like a high-risk, high-reward biotech that uses AI to generate drug formulas and sells or licenses its pipeline to Big Pharma.

  Risks

  Clinical trial failure, BD below expectations, downward revisions to PoS assumptions, friction in out-licensing, and regulatory uncertainty.

• XtalPi (2228.HK)

  China AIDD services, robotic wet lab, and platform infrastructure exposure

  Strengths

  AIDD services, automated robotic wet labs, physics-based algorithms, interests in 500+ collaborative projects, and AI4S plus the incubation model forming diversified growth engines.

  Weaknesses

  Physical laboratories and robotic facilities bring higher capital intensity, and valuation is more sensitive to AI-empowered EV/S multiples.

  Comparison

  Compared with Insilico, XtalPi is more like a platform service company that provides an AI kitchen and automated experimental infrastructure for drug R&D, while retaining interests in some proprietary or incubated assets.

  Risks

  Service revenue growth below expectations, slow progress in platform licensing, capital expenditure pressure, and robotic wet lab commercialization below expectations.

• China AIDD industry

  Cross-sector AI and pharmaceutical R&D theme

  Strengths

  The dry-wet lab closed loop, China’s R&D supply chain density, faster regulation, real-world clinical data, and Big Pharma partnerships together create execution advantages.

  Weaknesses

  The industry is still in the early commercialization stage, with no single winning platform yet, and revenue sustainability and model generalization capabilities still need validation.

  Comparison

  The report believes China AIDD benefits from domestic drug R&D efficiency and cost advantages, while overseas AIDD peers have higher valuations but may not enjoy the same China R&D infrastructure dividend.

  Risks

  Industry valuation pullback, technology route changes, insufficient data quality, cross-border licensing friction, and geopolitical and sanctions risks.

Key data

• Global AI-empowered drug R&D spending marketUS$11.9bn in 2023 to US$74.6bn by 2032E; 22.6% CAGRF&S forecast, reflecting pharmaceutical companies’ demand to shorten R&D cycles, reduce costs, and discover new targets.
• Global generative AI marketUS$37.4tn by 2032E; 25.8% CAGRThe report believes broad generative AI infrastructure also supports the commercialization of AIDD and adjacent areas such as materials and agriculture.
• Insilico PCC time and cost12 to 18 months; US$3mn to US$5mn per PCCThe report states that Insilico has compressed the average timeline from target discovery to PCC nomination from roughly 4.5 years traditionally to 12 to 18 months.
• XtalPi Hit-to-Lead time<2 months vs traditional ~2.5 yearsThe report cites this as evidence that XtalPi’s dry-wet lab closed loop and robotic experimentation capabilities improve efficiency.
• Implied 2027E P/S for XtalPi and InsilicoXtalPi 25x; Insilico 19xThe report believes this is below the overseas AIDD company average of approximately 63x to 66x.
• Target priceInsilico HK$71; XtalPi HK$10Both are initiation of coverage with Overweight ratings, with target prices as of Dec-2027.
• Current priceInsilico HK$48.44; XtalPi HK$7.04From the stock price and rating table on the report cover page.

Impact & implications

If the report’s judgment holds, China AIDD companies may shift from thematic valuation to a fundamentals-driven rerating powered by transactions, revenue, clinical data, and platform licensing. Insilico’s investment return depends more on key clinical readouts, pipeline out-licensing, and upward revisions to PoS; XtalPi’s investment return depends more on service revenue expansion, commercialization of robotic wet labs, broader AI4S applications, and platform multiple rerating.

Risks

• Clinical trial failure or key clinical readouts falling short of expectations.
• BD revenue, milestone payments, or out-licensing transactions below expectations.
• Intensifying drug licensing, regulatory, or geopolitical friction between the United States and China.
• U.S. sanctions or cross-border collaboration restrictions affecting the commercialization of AIDD companies.
• Failure of AIDD model generalization, leading to lower-than-expected R&D efficiency, success rates, or commercial value.
• Service-based revenue may show project-driven volatility, and revenue sustainability still requires ongoing validation.

What to watch

• Readouts and out-licensing progress for Insilico pipelines such as ISM001-055, ISM5411, ISM3091, ISM5043, ISM3412, and ISM6331.
• Commercialization progress of XtalPi’s SIGX2649, SIGX1094, robotic wet lab, AI4S, and incubation projects.
• The scale, upfront payments, milestones, and royalty terms of new collaborations between Big Pharma and China AIDD companies.
• The repeatability of AIDD service revenue, gross margin trends, and changes in cash burn.
• Changes in China NMPA’s regulatory framework and review timelines related to AI drug R&D.
• Changes in valuation multiples for overseas AIDD, CRO, robotics, and AI model companies.